AGs are probing OpenAI on health data and ads — right before its IPO
State AGs from multiple states are investigating OpenAI for possible user harm at the precise moment the company is preparing to go public. The collision of regulatory scrutiny and historic financial ambition is a genuine inflection point for the entire AI industry.
OpenAI's 'constructive' response and pre-existing safeguards signal a company that built compliance before regulators knocked — a standard IPO rite of passage.
Health data and ad policy subpoenas from unnamed AGs land in an IPO prospectus as 'material risk' — undisclosed scope is the investor's nightmare, not a footnote.
State AGs typically chase consent decrees, not fines — the real cost is operational curbs on the health and ad revenue lines OpenAI needs to justify its IPO multiple.
Hidden truth: AGs aren't probing OpenAI's AI risks — they're using ad-tech and health-data law, the same playbook that cost Google $391M in 2022.Read the full breakdown →
Is OpenAI's handling of health data a legitimate consumer safety concern?
